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Abstract
Background: From the original CftrTgH(neoim)Hgu mutant mouse model with a divergent genetic
background (129P2, C57BL/6, MF1) we have generated two inbred CftrTgH(neoim)Hgu mutant strains
named CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu, which are fertile and show normal growth and
lifespan. Initial genome wide scan analysis with microsatellite markers indicated that the two inbred
strains differed on the genetic level. In order to further investigate whether these genetic
differences have an impact on the disease phenotype of cystic fibrosis we characterised the
phenotype of the two inbred strains.
Results: Reduced amounts, compared to wild type control animals, of correctly spliced Cftr
mRNA were detected in the nasal epithelia, lungs and the intestine of both inbred CftrTgH(neoim)Hgu
strains, with higher residual amount observed for CF/1-CftrTgH(neoim)Hgu than CF/3-CftrTgH(neoim)Hgu for
every investigated tissue. Accordingly the amounts of wild type Cftr protein in the intestine were
9% for CF/1-CftrTgH(neoim)Hgu and 4% for CF/3-CftrTgH(neoim)Hgu. Unlike the apparent strain and/or tissue
specific regulation of Cftr mRNA splicing, short circuit current measurements in the respiratory
and intestinal epithelium revealed that both strains have ameliorated the basic defect of cystic
fibrosis with a presentation of a normal electrophysiology in both tissues.
Conclusion: Unlike the outbred CftrTgH(neoim)Hgu insertional mouse model, which displayed the
electrophysiological defect in the gastrointestinal and respiratory tracts characteristic of cystic
fibrosis, both inbred CftrTgH(neoim)Hgu strains have ameliorated the electrophysiological defect. On the
basis of these findings both CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu offer an excellent model
whereby determination of the minimal levels of protein required for the restoration of the basic
defect of cystic fibrosis can be studied, along with the modulating factors which may affect this
outcome.
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Cystic fibrosis (CF) is a severe autosomal recessive disor-
der characterised by defective chloride transport in epithe-
lial cells and excess mucus secretion. It is caused by
mutations in the cystic fibrosis transmembrane conduct-
ance regulator gene (CFTR), resulting in defective cAMP-
dependent chloride conductance [1].
Isolation of the mouse Cftr gene enabled the modelling of
the disease in the mouse by gene targeting in embryonic
stem cells. Dorin et al [2] described a transgenic mouse
model CftrTgH(neoim)Hgu/CftrTgH(neoim)Hgu, generated follow-
ing targeted insertional mutagenesis into exon 10 of the
murine Cftr gene in embryonic stem cells. Unlike the Cftr
mutants created by gene replacement low levels of wild
type Cftr mRNA were produced as a result of exon skip-
ping and aberrant splicing [3]. In the human, CFTR muta-
tions affecting the pre-mRNA splicing of the gene can also
generate both aberrant and correct transcripts, the level of
which varies among patients and among organs of the
same patient [4-8]. Patients carrying such mutations show
variability of disease expression, which has been found to
be inversely correlated with the levels of correctly spliced
transcripts, such that lower levels are associated with
severe disease and higher levels with milder phenotype,
suggesting a role for splicing regulation as a genetic mod-
ifier [9]. The original CftrTgH(neoim)Hgu/CftrTgH(neoim)Hgu
mouse suffered from only mild intestinal obstruction, but
it exhibited typical pathophysiological features of CF in
gut, lung and reproductive tract [2,10]. CftrTgH(neoim)Hgu/
CftrTgH(neoim)Hgu mutant mice displayed the electrophysio-
logical defect in the gastrointestinal and respiratory tract
characteristic of CF and could be unequivocally distin-
guished from their non-cf littermates (CftrTgH(neoim)Hgu/+
and +/+) on this basis [2,11]. The residual amounts of cor-
rectly spliced mRNA apparently led to the production of
some functional Cftr protein that was sufficient to amelio-
rate the otherwise fatal intestinal obstruction but not
enough to ameliorate the intestinal electrophysiological
disease phenotype [3].
From the original CftrTgH(neoim)Hgu mutant mouse model
[2] with a divergent genetic background we have gener-
ated two inbred CftrTgH(neoim)Hgu mutant lines named CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu using brother ×
sister mating for more than 30 generations. Phenotypic
evaluation of the inbred CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu animals indicated that both strains have
ameliorated the basic defect of CF with a presentation of
a normal electrophysiology in both the intestinal and
nasal epithelium. Unlike leaky splicing mutations in the
human the reduced amounts of correctly spliced mRNA
and the subsequent low amounts of wild type Cftr protein
substantiated for the restoration of the disease phenotype
in the two inbred CftrTgH(neoim)Hgu strains. Based on this
finding both CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu offer an excellent model to determine the
minimal levels of wild type Cftr required to ensure a nor-
mal chloride secretory capacity of the intestine preventing
intestinal obstruction.
There do exist a number of case reports in the literature of
how a deleterious mutation is partially corrected by the
affected patient. First, the interaction of drugs and/or pro-
teins with sequences in the 3' untranslated region may
lead to stabilisation of the mRNA transcript [12]. Second,
nonsense-associated altered splicing is a putative correc-
tional response that up-regulates alternatively spliced
transcripts that have skipped offending premature termi-
nation codons. Third, aminoterminal located nonsense
mutations may be partially rescued by the expression of
the partially functional amino-truncated protein gener-
ated from an alternative in-frame translation start site.
These attenuation mechanisms have been reported for
mild forms of non-Herlitz junctional epidermolysis bul-
losa [13], the laryngo-onycho-cutaneous syndrome [14]
and X-linked adrenal hypoplasia congenita [15]. Our CF
mouse model is a prototype of how a genuine lethal
genetic predisposition can be spontaneously bypassed or
compensated by post-transcriptional rescue.
Results
Generation of the inbred CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mutant mice
Dorin et al described in 1992 [2] the generation of the
transgenic CF mouse model CftrTgH(neoim)Hgu/
CftrTgH(neoim)Hgu. Targeted insertional mutagenesis into
exon 10 of the murine Cftr gene was performed in E14
embryonic stem cells (129P2 background). Correctly tar-
geted clones were injected into C57Bl/6 blastocysts. Male
chimeric mice were mated to outbred HsdOla:MF1
females [2].
In case of the Hannover pedigree, the male chimaera 40
was crossed with one MF1 female. The sibpair 40.15 from
this mating both mice of which were heterozygous
129P2/MF1 (CftrTgH(neoim)Hgu/+) became the founder
breeding pair (generation F0) for the Hannover mouse
lines. Transgenic CftrTgH(neoim)Hgu/CftrTgH(neoim)Hgu litterma-
tes were subjected to brother – sister mating. By genera-
tion F4 (that was sent to Hannover) the same
CftrTgH(neoim)Hgu/CftrTgH(neoim)Hgu male was mated with two
CftrTgH(neoim)Hgu/CftrTgH(neoim)Hgu female littermates. Two lit-
termates each from each litter became the founders of the
two individual inbred CftrTgH(neoim)Hgu strains CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu which were gen-
erated by strict brother-sister mating of CftrTgH(neoim)Hgu/
CftrTgH(neoim)Hgu homozygous mice for now more than 30
generations.Page 2 of 15
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CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice of
generation F26 were typed at a 20 cM spacing with micro-
satellite markers to assess their genome-wide status of
homozygosity and mutual genetic diversity. The criterion
for the selection of the first 78 markers was their informa-
tivity to differentiate between the three reference strains
BALB/c, C57BL/6 and DBA/2. Informative loci between
the two inbred CF strains were genotyped with flanking
markers in order to map the regions of genetic heteroge-
neity, bringing this to a total of 105 microsatellite mark-
ers.
Sixteen out of the 105 microsatellites were polymorphic
between CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu
[see Additional File 1] indicating that these two strains are
not identical to one another at all loci. Residual heterozy-
gosity was detected for eight microsatellites [see Addi-
tional File 1] three of which were segregating in both CF
strains. CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu dif-
fer from C57BL/6, BALB/c and DBA/2 strains in 58, 52
and 58 of the 105 markers, respectively [see Additional
File 1]. In summary, the two CF inbred strains are highly
similar to one another differing in eight chromosomal
regions, but they deviate significantly from the three com-
mon inbred laboratory strains C57BL/6, DBA/2 and
BALB/c.
Cftr mRNA analysis
In order to determine whether CF/1-CftrTgH(neoim)Hgu and
CF/3-CftrTgH(neoim)Hgu mutant animals produce correctly
spliced wild type Cftr mRNA as previously described for
their progenitor with a mixed genetic background [2,3] we
used RT-PCR spanning exon 9 to exon 13 encompassing
the vector insertion site, using wild type MF1 mouse as
control. Correctly spliced wild type Cftr mRNA corre-
sponded to a cDNA product of 555 bp in size. Sequencing
of the 555 bp PCR products obtained for the CF/1-
CftrTgH(neoim)Hgu mutant mice (ileum) revealed that the
observed reduced amounts correspond 100% to wild type
Cftr cDNA sequence. Moreover, a fragment of approxi-
mately 750 bp was detected in samples of homozygous CF
mutants but not in wild type animals. Sequencing of this
product demonstrated that it corresponded to the previ-
ously described [3] alternatively spliced mRNA encom-
passing the 206 bp fragment from the targeting vector
pIV3.5H spliced between exon 9 and exon 10. However,
this alternatively spliced mutant mRNA unlike in the orig-
inal report [3] was not consistently detected.
The amounts of total and correctly spliced wild type Cftr
mRNA in lungs and intestine were determined at different
stages of the inbreeding procedure (Table 1). The total
amount of Cftr mRNA did not significantly change over
time in lungs and intestine and was about 1- to 4-fold
Table 1: Cftr mRNA expression in CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice
Log (molecules Cftr mRNA)/µg RNA wild-type/total Cftr mRNA [%]
Total Cftr mRNAa wild-type Cftr mRNAb
F8 – F10 CF/1-CftrTgH(neoim)Hgu (n = 10)
Lung 4.7 ± 0.3 3.6 ± 0.3 7.9 ± 2.1
Intestine 5.1 ± 0.2 4.0 ± 0.2 7.1 ± 1.6
F18 CF/1-CftrTgH(neoim)Hgu mice (n = 6)
Lung 4.5 ± 0.3 2.9 ± 0.6 2.7 ± 1.9
Intestine 5.3 ± 0.2 4.0 ± 0.2 5.3 ± 1.3
F10 CF/3-CftrTgH(neoim)Hgu mouse (n = 1)
Lung 4.5 3.1 4
Intestine 5.0 3.6 4
F18 CF/3-CftrTgH(neoim)Hgu mice (n = 6)
Lung 4.9 ± 0.2 < 2 << 0.1
Intestine 5.1 ± 0.2 3.0 ± 0.5 0.8 ± 0.5
Ztm:MF1 mice (positive control, n = 4)
Lung 5.1 ± 0.2 5.1 ± 0.2
Intestine 5.3 ± 0.1 5.3 ± 0.1
Reference: log (molecules aldolase mRNA)/µg RNA = 7.26 ± 0.12
acDNA amplified by PCR with mmcftr primer pair A1 – A2;
bcDNA amplified by PCR with mmcftr primer pair B1 – B2 (see Methods section)Page 3 of 15
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outbred mice (Table 1). The absolute and relative
amounts of wild type Cftr mRNA, however, decreased
during inbreeding. CF/1-CftrTgH(neoim)Hgu mice of genera-
tions F8 – F10 had 7–8% of their Cftr mRNA correctly
spliced, whereas ten generations later the F18 mice were
carrying about 5% or 3% wild type Cftr mRNA in their
intestine and lungs, respectively (Table 1). In F18 CF/3-
CftrTgH(neoim)Hgu mice the amount of correctly spliced Cftr
mRNA had decreased below 1% in the intestine and was
at the limit of detection by RT/PCR (<< 0.1%) in the lungs
(Table 1). After we had detected Cftr immunoreative pro-
tein signals of differential intensity in the intestinal and
upper respiratory epithelia (see below), we reinvestigated
the contents of correctly spliced Cftr mRNA in F32 CF
mice. The levels of wild type Cftr mRNA in nasal epithe-
lium were determined to be 15% (CF/1-CftrTgH(neoim)Hgu)
and 2% (CF/3-CftrTgH(neoim)Hgu) of those of outbred
Ztm:MF1 mice. MF1 expressed more Cftr in the intestine
than in the nose; the relative levels decreased from duode-
num to jejunum and ileum. The pposite gradient was
observed in the F32 CF mice. No correctly spliced Cftr
mRNA was detectable in the duodenum of both CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu. The levels of
wild type Cftr mRNA in jejunum and ileum of CF/1-
CftrTgH(neoim)Hgu mice, however, were about 4% and close
to 10% of total Cftr mRNA, respectively. Consistent with
data from the F18 mice, CF/3-CftrTgH(neoim)Hgu showed
about five- to tenfold lower levels of correctly spliced Cftr
mRNA in jejunum and ileum, respectively than CF/1-
CftrTgH(neoim)Hgu mice.
Cftr processing in CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mutant mice
Analysis of brush border membrane vesicle (BBMV) prep-
arations consisting of apical membranes of mutant
homozygous F27 – F30 CF/1-CftrTgH(neoim)Hgu (n = 4) and
CF/3-CftrTgH(neoim)Hgu mice (n = 4) demonstrated the pres-
ence of fully glycosylated isoform (band C) of Cftr in the
small intestine of these mice (Figure 1). The intensity of
the C band of these mice was reduced when compared
with the intensity of the C band of the wild type MF1 mice
(n = 2). By running individual samples of the CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mutant mice
together with serial dilutions (5×, 10×, 20×, 50×, 100×) of
membranes from the MF1 wild type mice the amount of
mature CFTR (band C) in the two inbred mutant mice was
estimated to be 9.2 ± 1.5% of wild type for CF/1-
CftrTgH(neoim)Hgu and 4.2 ± 2.3% of wild type Cftr protein
for CF/3-CftrTgH(neoim)Hgu.
Phenotype of the inbred CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mutant mice
Growth and life-span of homozygous CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice improved
during inbreeding. Weight gain during the first months of
life increased from 23 ± 1.3 g at 3 months for
CftrTgH(neoim)Hgu mice of generation 8 to more than 30 g at
3 months for mice of generation 30 (CF/1-CftrTgH(neoim)Hgu:
females 29 ± 4 g, males 36 ± 2 g; CF/3-CftrTgH(neoim)Hgu:
females 32 ± 3 g, males 31 ± 3 g; Ztm:MF1 controls:
females 36 ± 3 g, males 43 ± 2 g). When we started
inbreeding, perinatal mortality was observed that peaked
at the time of weaning when 8–10% of litter died of intes-
tinal obstruction. Survival was 76% at the age of 3 months
for the F8 – F10 generations, and early deaths were still
observed in the F18 generation. CF/1-CftrTgH(neoim)Hgu and
CF/3-CftrTgH(neoim)Hgu mice of generation 25 or more, how-
ever, do not show any increased mortality over wild type
animals (pre-or post weaning). Both males and females
are fertile.
Histological analysis of intestinal sections from mice of
generations 27 and 28 revealed focal hypertrophy of gob-
let cells in the CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu homozygous mutant mice in the ileum
(Figure 2). However, this hypertrophy was not observed
in sections obtained from the jejunum in both inbred
CftrTgH(neoim)Hgu strains (Figure 2).
Cftr immunocytochemistry
In inbred F28 CF/1-CftrTgH(neoim)Hgu staining with the R3195
Cftr antibody revealed weak and mainly diffuse signals
with some apical labelling in the upper villus region of the
ileum, whereas no specific immunoreactive signals could
be detected in sections from duodenum and jejunum
(Figure 3). Sections of the intestine (duodenum, jejunum,
ileum) of F27 CF/3-CftrTgH(neoim)Hgu mice showed substan-
tially weaker staining at the limit of detection.
Cftr immunostaining of nasal respiratory epithelium (Fig-
ure 4) yielded strong punctuated apical labelling of simi-
Quantification of wild type Cftr protein in apical membranes (only band C present) of nterocytes of F28 CF/1-CftrTgH(neoim)Hgu (n = 4) and F27 CF/3-CftrTgH(neoim)Hgu (n = 4) m tant miceFigure 1
Quantification of wild type Cftr protein in apical membranes 
(only band C present) of enterocytes of F28 CF/1-
CftrTgH(neoim)Hgu (n = 4) and F27 CF/3-CftrTgH(neoim)Hgu (n = 4) 
mutant mice. Blots were labelled using the Cftr specific 
R3195 antibody.Page 4 of 15
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CftrTgH(neoim)Hgu and wild type MF1 and C57BL/6J mice.
Electrophysiological characteristics of CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu
The electrophysiological profile of F28 CF/1-
CftrTgH(neoim)Hgu and F27 CF/3-CftrTgH(neoim)Hgu mice both in
the nose and the intestine was examined by current meas-
urements in Ussing chambers under short-circuit condi-
tions. The chloride secretory responses of homozygous
CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu CF mice
were compared with those of inbred C57BL/6J and out-
bred MF1 non-CF mice. In the intestine, basal ion flow
was similar in wild type C57BL/6J and all examined CF
strains (Figure 5a) whereas MF1 exhibited a significantly
higher response. The chloride secretory response of the
two CF mutant strains evoked by forskolin amounted to
about 60% of that observed in MF1 wild type animals and
was higher than that of wild type C57BL/6J mice. The
response to carbachol was indistinguishable between CF/
1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu and C57BL/6
wild type mice. Noticeably, MF1 mice (outbred stock)
Alcian blue staining of deparaffinised sections of jejunum (A, B, C, magnification ×200) and ileum (D, E, F, magnification ×400) from wi d type MF1 (A, D) and mutant F28 CF/1-CftrTgH(neoim)Hgu (B, E) a d F27 CF/3-CftrTgH(neoim)Hgu C F) animals showed focal hypertroph  of goblet c lls i  the ileum of the two i bred CftrTgH(neoim)Hgu muta t miceFigu e 2
Alcian blue staining of deparaffinised sections of jejunum (A, B, C, magnification ×200) and ileum (D, E, F, magnification ×400) 
from wild type MF1 (A, D) and mutant F28 CF/1-CftrTgH(neoim)Hgu (B, E) and F27 CF/3-CftrTgH(neoim)Hgu (C, F) animals showed focal 
hypertrophy of goblet cells in the ileum of the two inbred CftrTgH(neoim)Hgu mutant mice. Goblet cell counts are given as percent-
age of all epithelial cells. From each strain two mice and three sections/mouse were counted. Goblet cell count: CF/1 = 22.7% 
± 2.3 (p = 0.112, p-value CF/1 compared to MF1), CF/3 = 23% ± 2.8 (p = 0.172, p-value CF/3 compared to MF1), MF1 = 16.8% 
± 1.2. The jejunal sections of the same mice did not show any signs of goblet cell hypertrophy and were similar to wild type 
MF1 (Goblet cell count: CF/1 = 7.4% ± 0.4 (p = 0.18, p-value CF/1 compared to MF1), CF/3 = 8.5% ± 1.2 (p = 0.77, p-value CF/
3 compared to MF1), MF1 = 8.8% ± 0.7.
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compared to wild type inbred C57BL/6J mice (almost
60% higher), indicative of an interstrain variation. In con-
trast genistein, which sustains the open state of CFTR
channels [16,17], generated higher short-circuit current
(Isc) currents in wild type C57BL/6J than in CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice.
In the nasal respiratory epithelium CF/1-CftrTgH(neoim)Hgu
and CF/3-CftrTgH(neoim)Hgu mice exhibited a higher response
after exposure to the sodium channel inhibitor amiloride
in comparison with MF1 wild type, but not in comparison
with C57BL/6J mice (Figure 5b). The forskolin activated
cAMP-triggered chloride secretory response was indistin-
guishable from wild type C57BL/6J in CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu. The response of
MF1 wild type mice was about two fold higher compared
to inbred C57BL/6J wild type animals.
Discussion
In contrast to mice with a complete disruption of the Cftr
locus, inbred CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mice like Cftrtm2Hgu and Cftrtm1Eur mutant
mice do not suffer from intestinal blockage. Unlike their
progenitor with a divergent genetic background [2,11],
the two inbred CF strains managed to ameliorate the elec-
Immunohistological analysis of CftrTgH(neoim)Hgu Cftr expressionFigure 3
Immunohistological analysis of CftrTgH(neoim)Hgu Cftr expression. Immunocytochemical staining of Cftr in the duodenum, jejunum, 
ileum of wild type mice MF1 (A, B, C), duodenum (E, magnification ×200), jejunum (F, magnification ×200) and ileum (G, magni-
fication ×400) of homozygous F28 CF/1-CftrTgH(neoim)Hgu and duodenum (H, magnification ×200), jejunum (I, magnification ×200) 
and ileum (J, magnification ×400) of F27 CF/3-CftrTgH(neoim)Hgu mice was performed with the R3195 anti-Cftr antibody as 
described in Methods. Wild type mice showed intense Cftr staining of the apical border of epithelial cells. In CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mutant mice Cftr staining was weaker and more diffuse mainly in the upper villus region. 
Ileum of a CF-Knock out mouse (D) was used as negative control.
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CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice to forskolin
was indistinguishable from wild type C57BL/6J in the res-
piratory epithelia and intermediate between wild type
C57BL/6J and MF1 control animals in the intestine. We
envisage that during inbreeding modulating mechanisms
were selected in these mice that influenced Cftr expression
at the level of transcript, protein and function.
Cftr splicing
Both novel inbred CftrTgH(neoim)Hgu showed the ability to
produce correctly spliced Cftr mRNA as previously
reported for their outbred progenitor with a mixed genetic
background in the respiratory and intestinal epithelia [3].
Interestingly, the total amount of Cftr mRNA did not
change during inbreeding, but the levels of correctly
spliced Cftr mRNA decreased to different extent in the two
mutant inbred strains, with CF/1-CftrTgH(neoim)Hgu showing
higher levels for every investigated tissue. CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu were divergent in
16 out of 105 microsatellite genotypes in the genome-
wide scan [18], verifying the genetic difference between
the two novel CftrTgH(neoim)Hgu inbred strains. This data sug-
gests that interstrain genetic variation at non-Cftr loci
could account for the phenotypic variation at the level of
Cftr splicing observed between the two novel mutant
strains.
In the intestine of both CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu the levels of Cftr expression are highest in
Cftr immunostaining in the nasal epithelium of wild type MF1 (A, magnification ×400), C57BL/6J (B, ×400), F30 CF/1-ftrTgH(neoim)Hgu (C ×400), F29 CF/3-Cf rTgH(neoim)Hgu (D, ×400)Figure 4
Cftr immunostaining in the nasal epithelium of wild type MF1 (A, magnification ×400), C57BL/6J (B, ×400), F30 CF/1-
CftrTgH(neoim)Hgu (C ×400), F29 CF/3-CftrTgH(neoim)Hgu (D, ×400).
A B
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jejunum and the duodenum. This tissue specific profile of
Cftr expression, which is similar between CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu could be due to
the existence of tissue specific elements which either
down-regulate (duodenum, jejunum) or up-regulate
(ileum, nasal epithelium) Cftr expression. Several splicing
factors such as SRs and hnRNPs have been shown to mod-
ify the splicing pattern of human transcripts carrying
splice mutations, overexpression of which can modulate
the splicing pattern of CFTR alleles carrying splicing muta-
tions [19-21], or affect tissue-specific control of CFTR
expression [22]. Whether the tissue specific levels of Cftr
expression depend on and/or are regulated by the levels of
such splicing factors in these two strains remains to be
investigated. Furthermore, in agreement with the previous
study on the original CftrTgH(neoim)Hgu mice with a mixed
genetic background [3] the novel mRNA species that con-
tained a 206 bp exon of vector sequence spliced between
exon 9 and exon 10 was occasionally observed in both
inbred strains. The 206 bp exon contains an in frame stop
at a position less than half way into the message [3]. Such
a premature stop codon may lead to exon skipping as has
been demonstrated in several human genetic diseases [23-
26] and could hence explain its inconsistent presence in
samples from homozygous CF mutant mice.
Cftr activity restoration: Efficient protein processing, 
trafficking and function
Regardless of the difference in correctly spliced Cftr mRNA
levels both CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu
mice synthesized and processed Cftr protein more effi-
ciently in the ileum than wild type animals. Starting from
small amounts of Cftr mRNA with wild type sequence, a
higher proportion of protein was adequately folded,
passed the ER quality control and was processed to com-
plex-glycosylated ('band C') Cftr isoforms. Apparently the
immature ER isoforms were more efficiently stabilised by
molecular chaperones and protected from degradation
than in normal mice.
The chloride secretory responses normalized to the pool
of band C Cftr were 5- and 10-fold higher in CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu intestinal epithe-
lia, respectively, than in wild type murine tissues. Several
mechanisms could account for the higher ion flow per
unit time and mass of mature Cftr in CF/1-CftrTgH(neoim)Hgu
and CF/3-CftrTgH(neoim)Hgu mice. First, short-circuit current
measurements are an indicator of transepithelial chloride
transport and thus do not directly measure Cftr chloride
channel activity. In wild type mice the transepithelial
import of chloride is rate limiting, but at the 10–20 fold
lower concentrations in our CF/1-CftrTgH(neoim)Hgu and CF/
3-CftrTgH(neoim)Hgu mice the Cftr mediated current is the rate
limiting step for chloride ion flow. At this lower density
the relatively larger electrochemical driving force for the
apical chloride exit will lead to relatively larger chloride
flow/channel. In addition, efficient Cftr trafficking from
the post-ER compartment to the apical membrane, along
with a reduction in the lysosomal degradation may result
in a higher proportion of mature protein localised in the
apical membrane compared to the subapical compart-
Short-circuit current (Isc) measurementsFigure 5
Short-circuit current (Isc) measurements. delta Isc repre-
sents the change in short-circuit current from baseline after 
addition of either forskolin, genistein, carbachol, or amilo-
ride. Upper panel. Bioelectric characteristics of the F28 CF/1-
CftrTgH(neoim)Hgu (n = 4) and F27 CF/3-CftrTgH(neoim)Hgu (n = 4) in 
the ileum compared with those of wild type MF1 (n = 5) and 
C57BL/6J (n = 4) mice. *, significant p-values compared to 
MF-1. Lower panel. Bioelectric characteristics of the F28 CF/
1-CftrTgH(neoim)Hgu and F27 CF/3-CftrTgH(neoim)Hgu in the nasal epi-
thelium compared with those of wild type MF1 and C57BL/
6J. The amiloride response is significantly increased in both 
CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice compared 
to MF1 wild type outbred mice. C57BL/6J inbred wild type 
mice exhibited less chloride secretion than MF1. The forsko-
lin evoked chloride secretion in both CF/1-CftrTgH(neoim)Hgu 
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu was reduced com-
pared to wild type MF1 but elevated compared to wild type 
C57BL/6J inbred mice.Page 8 of 15
(page number not for citation purposes)
BMC Genetics 2006, 7:18 http://www.biomedcentral.com/1471-2156/7/18ments. Various components have been shown to influ-
ence maturation and trafficking of CFTR from the ER/
Golgi compartment to the basolateral and apical compart-
ments, i.e. COPI-coated vesicles [27], PDZ-containing
proteins such as Csp [28], EBP50 [29,30], E3KARP [29],
CAP70 [31], CAL [32], SNARE proteins [33], BAP31 [34]
and numerous Rab proteins [35,36].
Third, the high ratio of forskolin to genistein Cl- secretory
responses suggests that even though there is a lower esti-
mated channel density in the CF/1-CftrTgH(neoim)Hgu and
CF/3-CftrTgH(neoim)Hgu compared to wild type in the apical
membrane, the proportion of active channels, i.e. in an
open state, is higher compared to wild type. The open
probability of the CFTR channel is influenced by phos-
phorylation and ATP hydrolysis [37] and by the interac-
tion with other proteins [38]. Phosphorylation of the
regulatory domain is accomplished primarily by elevation
of cAMP and activation of protein kinase A. Stronger
adrenergic activation and higher levels of cAMP will sus-
tain highly phosphorylated, more active CFTR channels.
Moreover, since CFTR channel activity increases with the
concentration of ATP [39], elevated intracellular ATP will
allow for more CFTR-mediated chloride flux. In summary,
higher yields of ion flow per unit mass mature Cftr can be
achieved by the larger electrochemical driving force for
the apical chloride exit and the modulation of a) post-
translational processing and trafficking, b) signalling and
c) metabolic rate. The repeated cycles of inbreeding
selected animals which were capable of producing suffi-
cient litters and showed no severe CF disease symptoms.
Hence, the rescue of CF to an almost normal phenotype in
mice which remained genetically CF can be explained by
the selection of genetic modifiers and adaptive mecha-
nisms together with modulators operating at the tran-
scriptional level. Our animal model is an extreme
example of how a lethal genetic predisposition can be
compensated.
Comparison with the human
CFTR splice mutations that lead to the simultaneous pres-
ence of correctly and aberrantly spliced transcripts cause
CF disease due to insufficient levels of the normal mRNA,
and hence, functional protein. Among these are muta-
tions leading to inclusion of intronic sequences, such as
3849+10 kb C-T [40], mutations leading to the skipping
of CFTR exons, such as 2789+5 G-A [41], and the TGm-Tn
genotype at the CFTR intron 8 splice acceptor site [42-44].
Studies have reported a wide range of normal CFTR tran-
scripts, from less than 4% to 20% [5,42,45] associated
with "leaky" splicing mutations in the human. Disease
severity also varies among individuals carrying these splic-
ing mutations, ranging from healthy fertile individuals to
the full presentation of classic CF. We know compound
heterozygous 2789+5 G-A CF siblings of whom one is suf-
fering from lung disease since adolescence, whereas the
other enjoys normal daily life without any restrictions of
physical activity still by the age of 60. An inverse correla-
tion was found between the level of the correctly spliced
mRNA and the severity of the disease [8,45]. In vitro stud-
ies in heterologous expression systems have shown that
cellular factors such as hnRNP A1, ASF/SF2, SR proteins
and TDP-43 that promote exon skipping and/or exon
inclusion modulate the relative proportions of correctly to
aberrantly spliced mRNA isoforms [21,46]. Moreover
splicing is controlled by cis-regulatory enhancer and
silencer elements part of which is under promoter control
[6,47,48].
The major difference in the genotype – phenotype corre-
lations of 'leaky' splice mutations between human indi-
viduals and the CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mouse models resides in the fact that the
manifestation of disease in humans is attenuated with
increasing amounts of correctly spliced CFTR mRNA
whereas the inbreeding of the mice selected for tissue spe-
cific modulation of lowered wild-type Cftr mRNA levels.
Under the standardised conditions of the animal labora-
tory post-transcriptional mechanisms apparently gave rise
to the rescue of the CF phenotype and the partial compen-
sation of the basic defect. These yet undescribed factors
that led to more efficient processing and higher channel
activity of Cftr should also play a role for the modulation
of disease in humans. The CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mice are the adequate model to identify
these beneficial modifiers that ameliorate the CF pheno-
type distal of the primary splicing defect.
Conclusion
In this study we describe the phenotypic characterisation
of two novel inbred cystic fibrosis mutant strains gener-
ated from an outbred colony of the original
CftrTgH(neoim)Hgu founder with a mixed genetic background
(129P2, C57BL/6, MF1). Unlike their outbred progenitor
low amounts of wild type Cftr protein substantiated for
the amelioration of the disease phenotype in both CF/1-
CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu inbred mutant
strains. The post-transcriptional rescue of disease-causing
mutations is an emerging field of molecular medicine
[49,50]. We envisage that both CF/1-CftrTgH(neoim)Hgu and
CF/3-CftrTgH(neoim)Hgu can become excellent models for the
identification of those mechanisms responsible of disease
compensation and will increase our knowledge about
genetic modifiers of inherited diseases in mammals.
Methods
Experimental animals
All experiments were approved by the local Institutional
Animal Care and Research Advisory Committee as well asPage 9 of 15
(page number not for citation purposes)
BMC Genetics 2006, 7:18 http://www.biomedcentral.com/1471-2156/7/18by the local government. CftrTgH(neoim)Hgu were bred under
specified pathogen-free conditions in the isolator unit of
the Central Laboratory Animal Facility of the Hannover
Medical School. Mice were kept in a flexible film isolator.
The temperature within the insulator was maintained at
20–24°C with 40–50% relative humidity. Animals were
fed an irradiated (50 kGy) standard chow (SSniff) and
autoclaved water (134°C for 50 min) ad libitum. CFTR
mRNA analyses were performed on Ztm:MF1, CF/1-
CftrTgH(neoim)Hgu (generations F8-F10, F18, F32) and CF/3-
CftrTgH(neoim)Hgu (generations F10, F18, F32) mice at the age
of 3 and 6 months. Bioelectrics, Cftr immunoblot and
immunocytochemistry were performed on female
Ztm:MF1, CF/1-CftrTgHeoim)Hgu (generations F28, F30) and
CF/3-CftrTgH(neoim)Hgu (generations F27, F29) mice at the age
of 3 months.
CF/1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice are
available for the scientific community upon written
request to HJH.
Generation of inbred CftrTgH(neoim)Hgu mutant mice
For the gene targeting and germline transmission to gen-
erate the CftrTgH(neoim)Hgu mice, the embryonal stem cell
line E14 was used [2]. E14 originates from the inbred
mouse strain 129 (subline 129/Ola-Hsd, abbreviated des-
ignation: 129P2) [2]. These cells were injected into blast-
ocysts of the inbred strain C57BL/6J. The resulting
chimeric offspring was crossed to C57BL/6J and to the
outbred strain MF1 for several times to increase reproduc-
tion [2]. By generation F4 the same CftrTgH(neoim)Hgu/
CftrTgH(neoim)Hgu male was mated with two CftrTgH(neoim)Hgu/
CftrTgH(neoim)Hgu female littermates. Two separate litters
were obtained and two animals of each litter became the
starting population for the establishment of the two indi-
vidual inbred CftrTgH(neoim)Hgu lines CF/1-CftrTgH(neoim)Hgu
and CF/3-CftrTgH(neoim)Hgu which were generated by
brother-sister mating for now more than 35 generations.
Only one breeding pair per generation was utilized for the
continuation of the line. In other words, littermates
always shared the same ancestors. Cftr genotyping from
tail or ear DNA extractions was conducted by Southern
blot hybridization of XhoI/SalI-restricted genomic DNA
with the cftr intron 10 probe 1.2 H [2].
Genotyping of microsatellites
High molecular weight DNA was isolated from spleen tis-
sue (from ten F26 CF/1-CftrTgH(neoim)Hgu, ten F26 CF/3-
CftrTgH(neoim)Hgu, two BALB/c, two C57BL/6 and two DBA/
2) [51]. The primers flanking the 105 chosen microsatel-
lite regions were obtained from the MGI database [52].
Microsatellite markers were genotyped in 96 well plates
purchased from Greiner, Frickenhausen, pre-coated with
50 ng DNA per well in a Hybaid Thermocycler (Hybaid,
Teddington) with a heated lid. One of the two primers per
microsatellite was 5'-terminal biotinylated (Invitrogen
Ltd). PCR was performed for all microsatellites in a total
volume of 30 µl, without oil overlay, using InViTaq
polymerase (InViTek, Berlin) according to the instructions
by the manufacturer. Following PCR an 8 µl aliquot was
transferred to a multiwell plate and allowed to dry over-
night at 37°C, dissolved in 10 µl loading buffer (0.2% w/
v xylenecyanol and bromphenolblue in formamide) and
denatured for 5 min at 95°C. The PCR products were sep-
arated by direct blotting electrophoresis (GATC 1500,
MWG Biotech, Ebersberg, Germany) on a denaturing acr-
ylamide gel (4% acrylamide/N,N'-methylenebisacryla-
mide 29:1 containing 6 M urea in 0.9 M Tris-0.9 M boric
acid-0.02 M EDTA buffer) and simultaneously transferred
to a Hybond N+membrane (Amersham). Signals were vis-
ualised by blocking the membrane in 1.5% (w/v) of
blocking reagent in Buffer 1 (100 mM Tris-HCl, 150 mM
NaCl, pH 7.5), followed by incubation in diluted solution
of anti-biotin alkaline phosphatase conjugate in Buffer 1.
The membrane was further washed three times with 1%
Triton X-100 in Buffer 1 and equilibrated for 15 min in
assay buffer (100 mM Tris-HCl, 100 mM NaCl, 50 mM
MgCl2, pH 9.5). The membrane was covered for 5 min
with reaction buffer containing 10%(v/v) Sapphire II
(Tropix) and 600 µl CDPstar (Tropix) (12.5 mM) in 50 ml
assay buffer, followed by rinsing with a solution contain-
ing 10% v/v Sapphire II and 60 µl CDPstar (12.5 mM) in
50 ml assay buffer. Signals were exposed to Kodak XA-R
films. Evaluation of results was performed as described by
Mekus et al [53].
Isolation of RNA and quantitative RT/PCR
All tissue samples from Ztm: MF1 and F8–10 as well as F18
CF mice were immediately frozen in liquid nitrogen after
extirpation and stored at -70°C until used. Prior to the
isolation of RNA, all solutions and plasticware were
treated for at least 12 h with 0.04% (by vol.) aqueous die-
thyl pyrocarbonate solution. RNA was isolated essentially
as described by Chomczynski and Sacchi [54]. Briefly, tis-
sue was ground with a pestle in a mortar under liquid
nitrogen and then homogenized in denaturing solution
(4 M guanidine thiocyanate, 25 mM sodium citrate, 0.5%
sarcosyl, 200 mM β-mercaptoethanol). The homogenate
was mixed sequentially with 1 M sodium acetate (pH 4),
phenol and chloroform/isoamyl alcohol; the mixture was
centrifuged and the RNA removed from the upper aque-
ous phase. Following isopropanol precipitation, the RNA
pellet was redissolved in denaturing solution, reprecipi-
tated with isopropanol, washed with ethanol, dried, dis-
solved in DEPC-treated water and stored at -70°C until
used. The quality of the preparation was checked by UV
spectrophotometry and ethidium bromide stain of 2 µg
RNA separated by 1% agarose gel electrophoresis. The
absence of contamination by DNA in the RNA prepara-
tion was verified by PCR with oald141N 5'-GGCAAG-Page 10 of 15
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TAACGGGCCAGAACATTGGCATT. These oligonucle-
otide primers yield a 421-bp product for both murine
genomic DNA and reverse-transcribed murine RNA (PCR
conditions per cycle: annealing at 62°C, synthesis at
72°C, denaturation at 92°C 60 s each).
For cDNA synthesis, 8 µg denatured RNA were added to
the 40-µl reaction volume of 40 U avian myoblastoma
virus reverse transcriptase, 120 µg/ml oligo(dT)15, 2000
U/ml RNasin, 0.9 mM dNTPs, 10 mM DTT, 75 mM KCl, 3
mM MgCl2, 50 mM Tris/HCl, pH 8.3, incubated for 1 h at
37°C, distributed in 10 µl aliquots and stored at -70°C for
a maximum of one month. The differential amounts of
total cftr mRNA and correctly spliced wild-type cftr mRNA
transcripts in specimens from CF/1-CftrTgH(neoim)Hgu and
CF/3-CftrTgH(neoim)Hgu mice were determined by quantita-
tive PCR kinetics modifying a protocol described by Hoof
et al [55]. Two oligonucleotide primer pairs A1–A2, B1–
B2 were designed upstream of and encompassing the neo
insertion site [2] (A1 mmcftr 1164–1189 5'-GCATTGTC-
CTACGTATGTCAGTCACG; A2 mmcftr 1524–1499 5'-
CCTAGTCCAGTAGATCCAGTAATAGC; B1 mmcftr 1499–
1524 5'-GCTATTACTGGATCTACTGGACTAGG; B2
mmcftr 2053–2032 5'-GCTCGGACGTAGACTTTGTAGC)
(GenBank Accession Number: NM_021050).
Amplification of Cftr cDNA stretches by PCR with these
primer pairs showed an identical kinetics of product for-
mation (∆cmax/cycle: ± 0.4% intestine; ± 1.3% lungs)
with Ztm:MF1 reverse-transcribed control RNA (PCR con-
ditions per cycle for both primer pairs: annealing at 58°C,
synthesis at 72°C, denaturation at 92°C 60 s each). For
quantitation of mRNA, the kinetics of cDNA formation
was monitored by incorporation of 1 × 105 Bq [α-
33P]dATP (> 1 × 1014 Bq/mmol) into cDNA. The PCR
assay (50-µl reaction volume covered with 60 µl mineral
oil) contained 0.5 µM of each oligonucleotide primer, 0.2
mM dNTP, 3 µl of oligoT-reverse transcribed reaction mix
(see above), 1.3 µl DMSO, 1.5 U Taq DNA polymerase
(InviTAQ), 7.5 mM MgCl2, 16 mM (NH4)2SO4, 50 mM
Tris/HCl, pH 8.8, 0.1% Tween.
Aliquots of the same oligoT-reverse transcribed reaction
mix were amplified in parallel in separate tubes in the
same blocks of the thermocycler with primer pairs A1–A2,
B1–B2 and oald141N-oald583I, respectively. During the
exponential phase of the amplification of the respective
cDNA aliquots of 10 µl were withdrawn in 2-cycle inter-
vals and separated by 5% PAGE. The dried gel was
exposed to a Fuji imaging plate type BAS-IIIs in order to
quantify the yield of cDNA product by photoimaging sig-
nal. For each RNA preparation, the optimal window of
PCR kinetics had been determined for each of the three
cDNA sequences in a prior pilot PCR. For quantification
of the cftr mRNA contents in the samples, data sets for
each murine tissue were normalized to its invariant aldo-
lase mRNA contents in order to adjust to the variable
quality of mRNA template in the RNA preparations and
assay-to-assay variability of the reverse transcription. This
approach was verified by the observation that the repeated
preparation of RNA from one tissue specimen showed
similar variations in aldolase cDNA kinetics as tissue
RNAs from unrelated animals. The quantitative amount
of cftr mRNA in the various samples was calculated from
the complete data set for one tissue whereby the experi-
mental curves log [cDNA] vs. PCR reaction cycle n were
converted into calibration curves cftr RNA molecules vs.
PCR cycle for various yields of cDNA [55]. Only those
datasets were evaluated that within experimental error
had given indistinguishable Cftr cDNA formation kinetics
with primer pairs A1–A2 and B1–B2 for reverse-tran-
scribed Ztm:MF1 RNA (positive control). Cftr mRNA con-
tents of each RNA preparation was assayed at least in
triplicate.
In case of the analysis of F32 CF/1-CftrTgH(neoim)Hgu and F32
CF/3-CftrTgH(neoim)Hgu animals the tissues (duodenum, jeju-
num, ileum, nose) were stored in RNAlater (Ambion)
after extirpation and stored at -20°C until use. RNA was
extracted using the RNAeasy mini kit (Qiagen) following
the instructions of the manufacturer. Extracted RNA was
stored at -80°C until use. The amount of aldolase and cor-
rectly spliced Cftr mRNA was determined by semiquanti-
tative RT/PCR kinetics. We titrated for the first reaction
cycle, when the gel-separated cDNA became visible by
ethidium bromide fluorescence during the late exponen-
tial phase of PCR [56]. This procedure yielded an estimate
of mRNA concentration within half an order of magni-
tude, whereas the interexperimental error of the quantita-
tive PCR on mRNA contents in F8–10 and F18 CF mice that
measured the incorporation of labelled nucleotide during
the exponential phase of PCR was twofold or less.
Sequencing
Following RT-PCR cDNA products were sequenced by
Qiagen GmbH.
Western blot analysis
Wild type MF1 mice and CF/1-CftrTgH(neoim)Hgu and CF/3-
CftrTgH(neoim)Hgu mutant mice were anaesthetized with a
hypnorm/diazepam mixture. Their abdomens were
opened and their small intestines dissected. Epithelial
cells originating principally from the villus region were
isolated at 0–4°C from the jejunum by everting the intes-
tinal segments on metal rods attached to a vibration appa-
ratus (Vibromixer type E1 from Chemap A.G.) and
exposing them to vibration (50 Hz, amplitude 1.5 mm)
for 30 min in 0.14 M NaCl containing 5 mM EDTA pH
7.4. Detached jejunal enterocytes were collected by cen-Page 11 of 15
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medium containing 12 mM Tris-HCl pH 7.4, 0.3 M man-
nitol, 10 mM KCl, 0.5 mM EDTA and a protease-inhibitor
cocktail containing 0.3 mM Pefablock (La Roche), 10 µg/
ml aprotinine, 5 µg/ml leupeptine, 1 µg/ml pepstatin A, 1
µg/ml chymostatin, 50 µg/ml soybean trypsin inhibitor
and 0.03 g/l phosphoramidon. Vesiculation of intestinal
membranes was achieved by a freeze-thaw procedure
described initially for rat enterocytes and crude micro-
somal membranes were isolated from half of the cell
lysate by a two-step differential centrifugation procedure
(10 min, 4000 g, followed by 60 min, 40 000 g). The other
half was used to isolate BBMV by differential precipitation
with 10 mM MgCl2 and differential centrifugation (15
min, 3000 g followed by 30 min, 27 000 g) essentially as
described by [57]. The membrane pellets were solubilized
by vortexing in 30 µl modified Laemmli sample buffer
[0.06 M Tris-HCl; 2% (w/v) SDS, 10% (w/v) glycerol, 0.1
M dithiothreitol, 0.1% (w/v) bromophenol blue and the
protease inhibitor cocktail, pH 6.8] and incubated for 30
min at room temperature. Following centrifugation (2
min, 8000 g) samples of the supernatant (10 µl, adjusted
to 20 µg protein) were separated on 6% polyacrylamide
slab gels using a Bio-Rad Miniprotean apparatus (Bio-Rad
Laboratories). Proteins were subsequently electroblotted
onto nitrocellulose paper (0.1 µm pore size; Schleicher
and Schuell) in 0.025 M Tris, 0.192 M glycine, 20% (v/v)
methanol. The blots were incubated overnight at 4°C
with 0.02 M Tris-HCl, 0.15 M NaCl, 0.1% (w/v) Tween 20
pH 7.5 (TTBS), followed by overnight incubation at 4°C
with a 1:1000 dilution of affinity-purified anti-CFTR anti-
body R3195 in TTBS. Blots were washed three times in
TTBS, incubated with peroxidase-conjugated anti-rabbit
IgG (Tago Inc.; 1:3000 in TTBS for 2 h), and washed four
times with TTBS. Peroxidase activity was detected with
bioluminescence reagent (ECL kit; Amersham) on X-ray
film, and CFTR bands were quantitated with the Molecu-
lar Imaging System GS-363 (Bio-Rad).
CFTR antibody
The rabbit polyclonal antibody R3195 was raised against
a thyroglobulin-conjugated 13 amino acid COOH-termi-
nal peptide sequence of rodent CFTR and was affinity
purified on a peptide epoxide-activated Sepharose col-
umn, eluted with 4.9 M MgCl2, dialysed and concen-
trated. CFTR labelling specificity has been demonstrated
previously in western blot and immunocytochemical
assays by the loss of immunostaining in tissue specimens
from CFTR-/- mice [58].
Immunocytochemical analysis
Intestine: Wild type (MF1 and C57BL/6J) and mutant CF/
1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu mice were sac-
rificed by cervical dislocation, the intestine was dissected
and the jejunum, duodenum and ileum were rinsed with
ice-cold saline and fixed in 3% (w/v) paraformaldehyde
for 16 h, prior to standard paraffin embedding. Sections
(5 µm) were deparaffinised, followed by microwave treat-
ment in 0.01 M sodium citrate solution according to
Devys et al. [59]. Endogenous peroxidase activity was
blocked by a 30 min pre-incubation in 0.1 M PBS, 0.6%
(v/v) H2O2 and 0.12% (w/v) sodium azide. Subsequently,
sections were incubated with antibody R3195 (1:100) at
room temperature for 1.5 h followed by a 60 min incuba-
tion with a peroxidase-conjugated secondary antibody.
Enzymatic detection of antigen-antibody complexes was
achieved by incubation in substrate solution containing
H2O2 and 3,3'-diaminobenzidine tetrahydrochloride
(DAB; Serva). Finally, the sections were counterstained
with haematoxylin. Labelling specificity was verified by
incubations without primary antibody. In both cases,
background labelling appeared negligible.
Nasal: Freshly excised nasal tissue from wild type MF1 and
C57BL/6J and mutant CF/1-CftrTgH(neoim)Hgu, CF/3-
CftrTgH(neoim)Hgu mice was used for immunocytochemical
analysis. The tissue was treated as described for the intes-
tine.
Histological analysis
Deparaffinised sections (5 µm) were stained with Alcian
blue (1% w/v in 3% v/v acetic acid, Sigma) for 30 min at
RT, rinsed in tab water and counterstained with Nuclear
fast red (Sigma) for 10 min.
Short-circuit current measurements
Freshly excised mouse ileum and nasal epithelium of CF/
1-CftrTgH(neoim)Hgu and CF/3-CftrTgH(neoim)Hgu homozygous
animals were used for short-circuit current (Isc) measure-
ments and compared with wild type controls. All experi-
ments were done in duplicate, n = the number of mice
used. Experiments were performed at 37°C. The basic per-
fusion solution (modified Meyler's solution) consisted of
105 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl2, 1.0 mM
MgCl2, 20.2 mM NaHCO3, 0.4 mM NaH2PO4, 10 mM
HEPES, saturated with 95% O2 and 5% CO2, pH 7.4.
Mouse ileum was excised under hypnorm/diazepam
anaesthesia and reverted on a plastic rod. The muscle layer
was cut longitudinally using a blunt razor blade and was
stripped of fat manually. The stripped tissue was mounted
in a holder with the mucosal side up (exposed tissue area
0.2 cm2). After insertion of the holder into the Ussing
chamber the tissue was allowed to recover for 10–20 min
and to reach a stable baseline. To the serosal side of the
ileum glucose (10 mM) and indomethacin (10 mM) were
added. After equilibrium, the following compounds were
added consecutively to the mucosal (M) or serosal (S) side
of the tissue: Forskolin (10 µM, S), genistein (100 µM,Page 12 of 15
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present throughout the experiment.
Mouse nasal epithelium was isolated as described by
Grubb et. al. [60]. In brief, the mice were sacrificed by cer-
vical dislocation and the skin of the head was peeled back
in order to reach the underlying paired nasal bones. These
were removed and the two sheets of the nasal epithelia,
separated by the septum, were isolated independently.
The sheets of epithelia were mounted immediately
between the Ussing chambers (exposed area 1.13 mm2).
The chambers were filled with gassed modified Meyler's
solution supplemented with glucose (10 mM) and
indomethacin (10 mM) and the short circuit measure-
ments were started. After equilibration amiloride (10 µM,
M) was added followed by forskolin (10 µM, after stabili-
zation of the current).
Statistics
P-values were determined by using the student's t-test. P-
values < 0.05 were considered significant.
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